Current Hematologic Malignancy Reports

期刊全称Current Hematologic Malignancy Reports
期刊缩写CURR HEMATOL MALIG R
涉及主题医学内科学生物免疫学遗传学心理学病理精神科血液学肿瘤科外科癌症研究化学生物化学疾病白血病细胞生物学重症监护医学癌症骨髓淋巴瘤干细胞化疗生物信息学移植髓系白血病
期刊介绍

his journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.

期刊ISSNprint: 1558-8211
历年影响因子
2024年 2023年 2022年 2021年 2020年 2019年 2018年 2017年
2.72.94.2133.9522.5312.3972.3882.029
历年发表/被引量
年份20252024202320222021202020192018201720162015201420132012
发表量526352955466363706154524140
被引量540144317411706196515781157952855741647529472414
h-Index28
自引率3.70%
涉及的研究领域ONCOLOGY-HEMATOLOGY
中科院2025年分区 ?
大类小类TOP期刊综述期刊
3区3区 血液学
3区肿瘤学
WOS期刊分区

JCR学科分类

JCR分区学科名称收录数据库JCR分区分区排名
HEMATOLOGYSCIEQ228/98
ONCOLOGYSCIEQ2123/326

JCI学科分类

JCI分区学科名称收录数据库JCI分区分区排名
HEMATOLOGYSCIEQ363/99
ONCOLOGYSCIEQ3233/326
期刊主页https://www.springer.com/11899https://www.springer.com/journal/11899
投稿网址https://www.editorialmanager.com/CHMR
出版商Springer US
出版国家(地区)UNITED STATES
出版语言English
出版周期6 issues per year
每年出版文章数55
Gold OA文章占比10.17%
原创研究文献占比
(排除综述)
0.00%
SCI收录类型

Science Citation Index Expanded (SCIE)

Scopus (CiteScore)

PubMed链接http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1558-8211%5BISSN%5D
平均审稿周期>12周,或约稿
平均录用比例较易
相关链接

您可以在上述网站查看该期刊的网友互动,及期刊影响力的其它指标。

注:上述信息均来源于网络,仅供查考,如有遗漏或信息错误,欢迎 向我反馈